IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Advanced Breast Cancer|Advanced Gastric Cancer
Interventions: DRUG: IMM2902
Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.